NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies develops and commercializes minimally invasive neurosurgical devices for diagnosing and treating brain and pain disorders. Its portfolio centers on FDA-cleared cortical and sEEG electrodes, radiofrequency ablation systems, and related electrode cable assemblies, with commercialization supported in part by a distribution agreement with Zimmer Biomet.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCortical strip/grid and sEEG electrodes used to record and monitor brain activity in epilepsy and related disorders.
Radiofrequency ablation products used for functional neurosurgery and pain-related lesioning.
Supporting hardware and cable assemblies sold with the company’s electrode-based systems.
Milestone and other payments tied to the Zimmer distribution and commercialization arrangement.
Customers
The company sells primarily to hospitals, neurosurgeons, and specialty medical centers that diagnose and treat epilepsy, Parkinson’s disease, trigeminal neuralgia, and chronic pain. Its products are used by clinicians who need minimally invasive tools for brain monitoring, lesioning, and stimulation, and by institutions that value FDA-cleared devices and reimbursement support. Zimmer Biomet is also a key commercial partner for distribution of selected brain products.
Buy cortical and sEEG electrodes for diagnosis and monitoring of epilepsy and other brain disorders.
Buy OneRF ablation systems for lesioning nerve tissue in pain and functional procedures.
Commercializes and distributes selected brain products, helping expand market access.
Support development, evaluation, and early adoption of new electrode and ablation technologies.
Strategy
The company’s strategy is to convert FDA clearances into broader commercial adoption across epilepsy, brain ablation, and pain indications. It is also extending the OneRF platform into trigeminal neuralgia and other pain markets while relying on Zimmer to help scale brain-product commercialization. Longer term, success depends on additional clearances, physician acceptance, and reimbursement support.
Revenue depends on converting cleared devices into routine clinical use.
New indications can expand the addressable market beyond current products.
External commercialization support can accelerate market penetration and reduce sales burden.
Geography
NeuroOne is headquartered and operationally concentrated in the United States, where all employees are located and where current commercialization is centered. The company also states that its products compete in U.S. and international markets, but the disclosed operating footprint in the filings is overwhelmingly domestic. Geography matters because the business depends on U.S. FDA clearance, U.S. physician adoption, and compliance with U.S. healthcare transparency rules.
Risks
The business remains highly dependent on regulatory clearance, physician adoption, and successful commercialization of a small product set. It also faces execution risk from third-party manufacturing, reimbursement, competition from larger device companies, and reliance on Zimmer for brain-product distribution. Because the company is still loss-making and capital-intensive, financing and liquidity risk remain material.
- Failure to commercialize or gain market acceptanceImpact: HighLikelihood: Medium
Revenue is concentrated in a small set of neurosurgical products that must win physician adoption.
Exposure - Dependence on Zimmer for distributionImpact: HighLikelihood: Medium
Zimmer has exclusive global rights for selected brain products, so execution by Zimmer directly affects sales.
Exposure: Brain product commercialization
- Capital and liquidity riskImpact: HighLikelihood: Medium
The company has recurring losses and needs external funding to support development and commercialization.
Exposure - Manufacturing and supplier disruptionImpact: MediumLikelihood: Medium
Products rely on third-party contract manufacturers and outside suppliers, which can constrain output and margins.
Exposure - Regulatory and compliance burdenImpact: MediumLikelihood: Medium
Medical devices face FDA, GMP, and Sunshine Act requirements; failures can delay sales or trigger penalties.
Exposure
Accounting
Judgemental itemsThe company has both product sales and Zimmer-related payments, which may be recognized differently and at different times.
Impact: Can shift quarterly revenue and gross margin
Small device volumes and product launches increase the risk of obsolete inventory and margin pressure.
Impact: Affects cost of product revenue and gross profit
Financing instruments may require mark-to-market accounting with non-cash gains or losses.
Impact: Can create volatility in net income
Royalty fees to intellectual property licensors are part of product cost structure.
Impact: Impacts gross margin and cash outflows
Similar listed companies
Publicly listed companies with a comparable business focus.
ClearPoint Neuro, Inc.
CLPT · Surgical & Medical Instruments & Apparatus
Zimmer Biomet Holdings, Inc
ZBH · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Zimmer Biomet Holdings is a U.S.-based medical technology company focused on orthopedic reconstruction and related surgical care.
Firefly Neuroscience, Inc
AIFF · Services-Prepackaged Software
NeuroPace Inc
NPCE · Surgical & Medical Instruments & Apparatus
NeuroPace is a U.S.-based medical device company focused on epilepsy treatment through its implantable RNS System.
NeuroSense Therapeutics Ltd.
NRSNW · Pharmaceutical Preparations
NRX Pharmaceuticals, Inc.
NRXP · Pharmaceutical Preparations
Last updated: 24/09/2026